The T-cell Lymphoma Market Size is valued at 1512.0 Million in 2022 and is predicted to reach 3313.7 Million by the year 2031 at a 9.2 % CAGR during the forecast period for 2023-2031.
Key Industry Insights & Findings from the Report:
- The rising incidence of T-cell lymphomas globally, particularly in ageing populations, drives the demand for effective treatments and therapies.
- Growing awareness about T-cell lymphomas and an increase in healthcare spending are enabling better diagnosis and treatment, particularly in developing regions, thereby propelling market growth.
- North America dominated the market as well as accounted for a global revenue share in the year 2023.
- The presence of alternative therapies, including more established treatments for other types of lymphomas, can limit the market potential for new T-cell lymphoma treatments.
T-cell lymphoma is a rare type of cancerous lymphoma that begins in white blood cells (T cells). Lymphoma arises from the uncontrolled growth of mature T cells and can become cancerous. It can cause skin redness, scaly round patches on the skin, and skin tumors.
Several factors driving the growth of the T-cell Lymphoma Market include the rising lymphoma cancer cases, increasing technological advances in therapy techniques, increasing T-cell lymphoma-specific therapies, and increasing autoimmune disorders. Moreover, spreading awareness regarding the benefits of T-cell lymphoma therapeutics, surging demand for cost-efficient cancer treatments and boosting government funding for the R&D of innovative cancer therapies are further expected to deliver considerable market growth during the forecast period. According to Leukemia & Lymphoma Society 2020, around 85,720 new lymphoma cases were diagnosed in the United States in 2020. Additionally, the newly reported lymphoma cases include 8,480 cases of Hodgkin (HL) and 77,240 cases of Non-Hodgkin (NHL) Lymphoma, thereby upsurging the demand for this market.
However, the high cost of T-cell Lymphoma therapies, complicated production methods, and side effects of these therapies may restrict the market growth in the upcoming years.
Competitive Landscape
Some major key players in the T-cell Lymphoma Market:
- 4SC AG,
- Acrotech Biopharma,
- Affimed,
- Bausch Health Companies Inc.,
- Biocryst Pharmaceuticals Inc.,
- Bristol-Myers Squibb Company,
- Chipscreen Biosciences,
- Citius Pharma,
- CSPC,
- CStone Pharmaceuticals,
- Daiichi-Sankyo,
- Dizal Pharma,
- Eisai,
- Elorac,
- Hoffmann-La Roche Ltd,
- Genmab A/S,
- Genor Biopharma,
- GlaxoSmithKline plc.,
- Innate Pharma,
- Johnson and Johnson Private Limited,
- Kyowa Kirin Co., Ltd.,
- Merck and Co. Inc.,
- Novartis AG,
- Pfizer,
- Roche,
- Seagen Inc.,
- Secura Bio,
- Shanghai Junshi Bio,
- SHIONOGI & Co., Ltd.,
- Solasia,
- Spectrum Pharmaceuticals Inc.,
- Takeda,
- Viracta,
- Other Prominent Players
Market Segmentation
The T-cell Lymphoma Market is classified based on lymphoma type, therapy, and region. By lymphoma type, the market is segmented into peripheral T-cell lymphoma and T-cell lymphoblastic lymphoma. Peripheral T-cell lymphoma is further divided into cutaneous T-cell lymphoma, anaplastic large cell lymphoma, angio-immuno-blastic T-cell lymphoma, and others (intestinal T-cell lymphoma, follicular T-cell lymphoma). By therapy, the market is grouped into radiotherapy, chemotherapy, immunotherapy, stem cell transplantation, and others (antiviral treatment, etc.). The chemotherapy segment is expected to lead this market during the forecast years due to its increasing use for cancer treatments. Regionally, the market is segregated across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. North America is anticipated to dominate the T-cell lymphoma market over the forecast period (2020-2030), owing to the increasing R&D expenditure and rising incidences of lymphoma in this region.
T-cell Lymphoma Market Report Scope
|
Report Attribute |
Specifications |
|
Market size value in 2022 |
USD 1512.0 Million |
|
Revenue forecast in 2031 |
USD 3313.7 Million |
|
Growth rate CAGR |
CAGR of 9.2 % from 2023 to 2031 |
|
Quantitative units |
Representation of revenue in US$ Million and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2023-2031 |
|
Report coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments covered |
Therapy, Lymphoma Type |
|
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
4SC AG, Acrotech Biopharma, Affimed, Bausch Health Companies Inc., Biocryst Pharmaceuticals Inc., Bristol-Myers Squibb Company, Chipscreen Biosciences, Citius Pharma, CSPC, CStone Pharmaceuticals, Daiichi-Sankyo, Dizal Pharma, Eisai, Elorac, F. Hoffmann-La Roche Ltd, Genmab A/S, Genor Biopharma, GlaxoSmithKline plc., Innate Pharma, Johnson and Johnson Private Limited, Kyowa Kirin Co., Ltd., Merck and Co. Inc., Novartis AG, Pfizer, Roche, Seagen Inc., Secura Bio, Shanghai Junshi Bio, SHIONOGI & Co., Ltd., Solasia, Spectrum Pharmaceuticals Inc., Takeda, Viracta, and Other Prominent Players. |
|
Customization scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and available payment methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
